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Abstract 
At present, secondary immune deficiencies have become a clinical problem, recognized in different 
specialties. The aim of this paper was to increase awareness and support the need for screening at-risk 
populations. Secondary immune deficiencies result in variety of conditions, but not all of them require 
immunoglobulin replacement therapy, as specific antibody response might be preserved. Moreover, the 
management of secondary immune deficiencies vary between countries and different medical disciplines. 
This literature review presents the most common causes and clinical presentation of secondary immu-
nodeficiencies with predominant impaired antibody production. We present diagnostic guidelines for 
patients at-risk, with an emphasis on the role of prophylactic vaccination as a treatment and diagnostic 
tool. This review considers the specificity and disparities of the Polish healthcare system and ultimately, 
suggests that management teams should include a clinical immunologist experienced in the treatment 
of humoral immunodeficiencies. 
Key words: secondary hypogammaglobulinemia, diagnostic workup, immunoglobulin substitution, 
antibody deficiency, rituximab, subcutaneous immunoglobulin. 
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Introduction 
Presently, secondary immune deficiencies (SIDs) have 
become a clinical problem, recognized in different special-
ties [1]. SIDs result in a variety of conditions, but not all of 
them require immunoglobulin replacement therapy (IgRT), 
as the specific antibody response might be preserved. 
The major causes of SIDs in western and central Eu-
rope countries include hematological malignancies, main-
ly, chronic lymphocytic leukemia (CLL), multiple myelo-
ma (MM), and non-Hodgkin lymphoma. Iatrogenic causes 
include the use of biological therapies, especially targeted 
B cells, hematopoietic stem cell transplantation [HSCT], 
and solid organs transplantations [SOT], and further ex-
pands the list of specialists involved in care of patients 
with SID (Table 1). However, the management of SIDs 
varies regionally and among different specialists [1, 2]. 
Current clinical practice does not always reflect treatment 
guidelines, highlighting the need for robust clinical studies 
on IgRT in SIDs, and coordination between countries and 
disciplines [2]. An international online survey of 230 phy-
sicians responsible for the diagnosis of SID and prescrip-
tion of IgRT in patients with hematological malignancies, 
showed that serum immunoglobulin was measured in 83% 
of patients with MM, 76% with CLL, and 69% with non – 
Hodgkin lymphoma [2]. Most physicians (85%) prescribed 
IgRT after ≥ 2 severe infections. In Italy, Germany, Spain, 
and the United States, immunoglobulin use was above 
average in patients with hypogammaglobulinemia, while 
considerably fewer patients received IgRT in the UK. The 
use of subcutaneous immunoglobulin (SCIG) was highest 
in France (34%) and lowest in Spain (19%). In addition, 
recent data show that IgG monitoring during IgRT is not 
always conducted [3]. 
There are no published data for Poland regarding any 
aspects of SIDs and IgRT. Polish data from primary im-
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mune deficiency (PID) indicated that immunology diag-
nostic procedures are not wildly recognized. Despite rec-
ommendations, vaccination response is assessed in 20% 
of adult patients [4]. Patients with a risk of SID sometimes 
first undergo an immunologic test on a life-threatening in-
fection [5]. Moreover, in Poland, SCIG home therapy is 
not reimbursed for SID patients, although it is increasingly 
used in PID [4, 6]. More important problem that is com-
monly faced is the limited access to intravenous immuno-
globulin (IVIg) products; therefore, prescription of IgRT 
in SID should be well-balanced and justified. 
The aim of this paper was to increase the awareness 
among different specialties and support the need for SID 
screening in at-risk populations. The review considers the 
specificity and gaps of the Polish healthcare system. All 
authors are responsible for diagnosing immunodeficien-
cies and prescribing IgRT as clinical immunologists (all 
authors), hematologists (WJ, AT) as well as a rheumatol-
ogist (EWS) and a pulmonologist (KJR). Moreover, some 
of the authors (KJR, MS, EWS) participate in Polish drug 
programs as members of coordinating teams [7]. 
SID clinical aspects 
SID in chronic lymphocytic leukemia and 
multiple myeloma 
In chronic lymphocytic leukemia (CLL), abnormalities 
of immune system function may affect up to 85% of patients 
[8, 9]. The most common infections are common respiratory 
and urinary tract infections (UTIs). In immunosuppression 
naive patients, they are 60% of bacterial, 25% of viral, and 
less common fungal (7%) infections. The most popular eti-
ological factors of respiratory infections are Staphylococcus 
aureus, Streptococcus pneumoniae, and Hemophilus influ-
enzae, while in UTIs, it is Escherichia coli. In the course of 
chemo-immunotherapy used in the treatment of CLL, reac-
tivation of latent viral infections may occur, e.g., with HBV. 
Treatment with purine analogues that interfere with DNA 
synthesis reduces CD4+ T cell, lymphocyte, and monocyte 
counts, which lead to an increased risk of opportunistic in-
fections caused by microorganisms, such as Listeria mono-
cytogenes, Mycobacterium spp., Pneumocystis jiroveci, 
Herpes simplex, Varicella zoster, Candida spp., Aspergillus 
spp., and Cryptococcus spp. [10]. 
Hypogammaglobulinemia is the main factor correlat-
ing with an increased risk of infections in CLL. A low 
concentration of at least one of the major immunoglobulin 
classes is found at an early stage of the disease, regardless 
of the tumor mass and often before initiation of cytotox-
ic treatment. Along with disease duration or progression, 
immunoglobulin deficiency extends to 2 or 3 classes [11]. 
In a study by Freeman et al., hypogammaglobulinemia 
was found in 23% of 150 patients, out of which 64.6% 
had deficiency of at least one IgG subclass, usually IgG3 
Table 1. Causes of the most common secondary immuno-
deficiencies, mainly humoral type [1, 8, 25, 28, 30, 32, 33, 
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* specific antibody response preserved despite hypogammaglobulinemia 
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[11]. In 8% of patients with severe recurrent infections, 
the IgG level was normal, with concurrent deficiency of 
at least IgG subclass [11]. In CLL patients, an association 
was found between IgG and IgA deficiency and increased 
mortality due to bacterial infections [12]. 
In patients with multiple myeloma (MM), bacterial in-
fections occur at a rate of over 25% and at one-year follow 
up, they were the underlying cause in 22% of deaths in 
MM. Compared with healthy controls, MM patients have 
reduced antibodies specific for pneumococci, tetanus, 
diphtheria, varicella, mumps, measles, and staphylococcal 
alpha-toxin [13, 14]. Infection risk is the highest in the 
course of chemotherapy, especially in the initial period of 
the disease, but also, it persists in the plateau phase. Typi-
cal infections in MM patients are RTI, UIT, septic compli-
cations, pneumonia, and meningitis [13, 15]. Savage et al. 
observed a biphasic pattern in bacterial infections of MM 
[16]. In 57 patients with MM, 75 infections were analyzed. 
S. pneumoniae and H. influenzae occurred at presentation 
and in early stage of the disease, while Gram-negative bac-
teria and S. aureus were responsible for infections in the 
advanced phase of diseases and in neutropenic patients, 
being the cause of death for 92% of patients [16, 17]. Al-
though these studies were performed nearly 40 years ago, 
this bipolar pattern of infections is still present in clinical 
practice and affects different modes of management. 
SID after transplantation of hematopoietic stem 
cells and solid organs 
Infectious complications are one of the most common 
causes of deaths in patients after HSCT and SOT [18]. 
These procedures are associated with a significant risk of 
immunosuppression development, which often overlaps 
with immunodeficiency caused by the underlying disease 
and its previous treatment [18-20]. Restoration of an im-
mune system after transplantation is one of the most im-
portant factors that influence the outcome [21, 22]. In this 
group of patients, SIDs are common, with usually complex 
pathogenesis, appearing early after transplantation, and 
may persist for months or even years. Depending on time 
after transplantation, a deficiency of immunocompetent 
cells, deficiency of antibodies, or mixed deficiency might 
dominate [21-23]. Many pre-and post-transplantation fac-
tors influence immune restoration, including the recipient’s 
age, underlying disease diagnosis and its advancement at 
the time of transplantation, previously used methods of 
treatment, degree of HLA compatibility between the re-
cipient and donor, source of hematopoietic cells, intensity 
of conditioning, carriage of latent viruses (especially CMV 
and EBV) by the recipient and donor, and development 
of graft-versus-host disease [21]. Three basic periods that 
differ by abnormalities of the immune system and the spec-
trum of observed infections are arbitrarily defined: phase 
I is the early (pre-engraftment) phase, when the main risk 
factors are neutropenia and breakdown of anatomical bar-
riers (e.g., gastrointestinal mucositis, presence of a central 
venous catheter), and includes the time between the trans-
plantation date (day 0) and ca. day +30 post-transplanta-
tion, i.e., hematological reconstitution; phase II includes 
days +31 to +100, with accompanying cellular and humor-
al immunodeficiency, often related to treatment of acute 
graft-versus-host disease; and phase III is after day +100, 
when humoral immunodeficiencies predominate, and is of-
ten associated with chronic graft-versus-host disease and 
its treatment [13, 19]. At the same time, hypogammaglob-
ulinemia in transplantation patients was shown to be asso-
ciated with a significant risk of infectious complications, 
especially pneumonia, CMV infections, invasive fungal 
infections, and death [19, 24]. 
SID in the course of biological therapies 
Biologics, as targeted treatments, significantly inter-
fere with response mechanisms of the immune system. In 
particular, hypogammaglobulinemia occurs after the use of 
treatments that inhibit B cell response [25, 26]. In an anal-
ysis of a large group of patients with type B lymphomas 
published in 2013, in 6.6% of the patients, IgG deficiency 
was associated with increased susceptibility to infections, 
which prompted IgRT initiation [27]. Symptomatic hy-
pogammaglobulinemia was defined as 2 or more non-neu-
tropenic infections that occurred within 6 months. These 
were mainly sinusitis and pneumonia. The risk factors of 
infections in patients with hypogammaglobulinemia were 
at least 2 doses of rituximab and coexisting low levels of 
IgM or IgA. The pre-treatment IgG level, exposure to pu-
rine analogues, sex, and age (≤ 65 years vs. > 65 years) 
as well as histological type of cancer had no impact on 
infection risk [27]. 
SIDs are also an increasing problem in patients with 
autoimmune diseases treated with rituximab [28]. In the 
described case series, an increased risk of hypogamma-
globulinemia in patients with vasculitis and optic neuritis 
was confirmed [29, 30]. In a group of 101 patients treated 
with rituximab for various indications, “catastrophic in-
fectious syndrome” occurred in 10 (9.9% of the analyzed 
group) patients and was fatal in 7 [31]. In contrast, hy-
pogammaglobulinemia was a rare complication of ritux-
imab treatment in patients with rheumatoid arthritis [32, 
33]. However, in clinical trials (8 randomized trials and 
2 open-label extension trials), exclusion criteria were 
IgG < 5.65 g/l and IgM < 0.55 g/l. It is a challenge to iden-
tify early patients at risk for the development of symptom-
atic hypogammaglobulinemia. Different predisposing fac-
tors were suggested depending on the population studied, 
treatment protocol, and follow-up period. A low IgG level 
before rituximab treatment, cumulative cyclophosphamide 
dose, and higher cumulative corticosteroids exposure were 
reported, but were not confirmed in all studies [27, 34-36]. 
In Poland, the access to rituximab in autoimmune dis-
eases other than rheumatoid arthritis has so far been limit-
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ed. In connection with the introduction of a drug program 
and increased use of rituximab in systemic vasculitis, we 
can expect a larger number of SID patients treated with 
rituximab, secondary to B cell depletion therapy. 
To date, no reports on groups of SID patients, who 
would require IgRT after the use of other biologicals were 
found in the literature. The initial reports of high-risk se-
vere infections and hypogammaglobulinemia in patients 
with systemic lupus erythematosus (SLE) treated with 
atacicept (TACI receptor antagonist) in combination with 
mycophenolate mofetil, have not been confirmed in sub-
sequent clinical trials [37]. Belimumab, an anti-BLYSS 
monoclonal antibody approved for the treatment of SLE, 
and abatacept (a second signal inhibitor) have to date been 
considered as safe [38]. However, these data may change 
along with an extension of their therapeutic indications and 
a longer period of observation in everyday practice. 
Diagnosis of SID 
In 2014, European consensus statement on the deter-
mination of serum Ig concentrations and the levels of spe-
cific serum antibody titers in response to vaccination was 
obtained upon as a useful approach for patients’ selection 
in SID, although the need for more research was acknowl-
edged [39]. 
Evaluation of vaccination response is a critical ele-
ment of the diagnostic workup [40-42]. It is recommended 
to test the response to vaccination against pneumococci 
with the use of a polysaccharide vaccine PPV23. Also, an 
assessment of specific antibody levels should be measured 
before vaccination as well as at 4-8 weeks and 6 months 
after vaccination, to identify patients with an early loss 
of response to vaccination [43]. Pasiarski et al. reported 
an increase in plasmablast percentage in the blood one 
week after a 13-valent pneumococcal conjugate vaccina-
tion [44]. 
Currently, the measurement of specific antibody re-
sponses varies across countries. Physicians from Spain, 
Italy, and the USA measure specific antibody responses 
more frequently than physicians in general. In the UK and 
the Republic of Ireland, specific antibody responses are 
mostly measured after PPV23 vaccination (referred to as 
test immunization) [45]. Clinical immunologists measure 
immunologic response more often than other specialists. 
In an international survey, two – thirds of immunologists 
and only one-third of physicians reported performing im-
munizations tests [2]. 
In Poland, PPV 23 is currently unavailable, but lack of 
response to the conjugated pneumococcal vaccine might be 
a criterion for IgRT. An alternative to PPV is testing the 
response to Salmonella typhi vaccine [46]. In our opinion, 
reimbursement of the cost of the vaccine and vaccination 
response before IgRT as well as greater awareness among 
physicians could increase the vaccination load. 
Treatment 
Preventive vaccination 
There has been a long-lasting discussion of vaccination 
safety and efficacy in chronic inflammatory diseases and 
malignancy. We would like to underscore that for all pa-
tients with a high-risk of SID, selected types of preventive 
vaccination should be considered [47, 48] as a therapeu-
tic option. For example, a special vaccination programme 
has been developed for transplantation patients [49, 50]. 
In CLL patients, pneumococcal conjugate vaccine is rec-
ommended. It has also been demonstrated that it is im-
portant to vaccinate the patient as early as possible after 
CLL diagnosis, when normal immunoglobulins are still 
produced, which ensures better protection after vaccina-
tion [51]. Annual preventive vaccination against influenza 
is also recommended [47, 48]. Vaccination status should 
be carefully assessed in patients with autoimmune diseases 
qualified for rituximab treatment. Non-live vaccinations 
should be administered at least 4 weeks prior to B cell-de-
pleting therapy [52]. 
Replacement treatment with polyclonal 
immunoglobulin G 
Institution of IgRT should not be based solely on the 
IgG result. Eligibility for IgRT should consider severity of 
infections, concentrations of IgG subclasses, vaccination 
response, and an assessment of efficacy of prophylactic 
antibiotic treatment [36, 40]. The guidelines underscore 
IgRT only when functional antibody deficiency is proven, 
independent of a particular threshold level of IgG, which 
may be even as low as 2.0 g/dl [28, 40]. 
The available data on the effects of immunoglobulin 
replacement in SID showed that it did not reduce mortality. 
In CLL and MM, randomized trials have been conducted 
in patients with hypogammaglobulinemia and infections 
[53-59]. In the IVIG-treated group, the infection rate was 
lower, antibiotic requirements were reduced, and hospi-
talization duration was shorter. Limitations of the above 
studies were small patient groups and relatively short fol-
low-up periods. Therefore, it is recommended to consider 
replacement in individual cases of patients with CLL, hy-
pogammaglobulinemia, and recurrent infections [60, 61], 
and with MM, hypogammaglobulinemia, and life-threat-
ening infections [62]. Also, in patients after allo-HSCT 
and SOT, data on Ig replacement (with both polyvalent 
and hyperimmune immunoglobulins) are inconclusive, and 
no uniform guidelines have been formulated so far [9,19]. 
Several randomized trials have investigated the efficacy 
of IVIG in the prevention and/or treatment of bacterial, 
fungal, and viral infections (especially with cytomegalo-
virus) in cell and organ transplant recipients as well as in 
the prophylaxis and modification of acute graft-versus-host 
disease (aGvHD) [9, 63-65]. However, conflicting results 
were obtained, and one of the trials demonstrated an ele-
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vated risk of hepatic-occlusive disease (VOD/SOS) [65]. 
Different dosage regimens and immunoglobulin products 
were used in these trials in heterogeneous patient groups 
[9, 18, 19, 65]. The assessment of efficacy and cost-effec-
tiveness as well as the safety of such an approach, especial-
ly in the context of the use of modern infection prophylax-
is, raises some concerns [18, 19]. 
Methods of administration and experience in SID
IgRT can be administered intravenously (IVIG), sub-
cutaneously (SCIG), and via hyaluronidase-facilitated sub-
cutaneous route (fSCIG) [66-70]. The intravenous route is 
associated with the need for hospitalization and providing 
venous access. IVIG administration is related to systemic 
adverse effects that result, for example, from high IgG se-
rum levels immediately after the procedure [66]. Severe 
complications, such as hemolysis, cardiovascular events, 
and renal failure, are rare [66]. SCIG and fSCIG are saf-
er methods and do not require vascular access [68]. Be-
cause of the limitation of administered volume to 60 ml 
per single site, subcutaneous use (SCIG) requires dosage 
at intervals of usually one week, often at several different 
injection sites, but treatment can be conducted at home 
after appropriate patient’s training [67, 68]. SCIG provides 
very stable IgG levels and can be administered by pump or 
by rapid-push (manual method), depending on the selected 
Ig product [68]. FSCIG is a method where, due to prior ad-
ministration of hyaluronidase, it is possible to inject higher 
individual Ig volumes and dosages into the subcutaneous 
tissue (up to 500 ml at a single site), with a frequency sim-
ilar to intravenous products. FSCIG is given via pump in 
a home setting also [69,70]. Existing experiences with PID 
indicate benefits from the use of subcutaneous products, 
which are the preferred Ig replacement method in PID [68, 
71]. Clinically, SCIG and fSCIG are used in SID, with 
good outcomes and a favorable safety profile [3, 72-74]. 
A recently published study showed that among patients 
with SID due to hematologic malignancy, 68% received 
conventional SCIG and 84% of them received the treat-
ment via home-based administration [3]. However, clear 
reasons for classification of patients to specific modes of 
administration were not given. Formal clinical trials have 
not been conducted for the use of SCIG and fSCIG in SID. 
Recommended doses depend on the product type 
and are usually 0.2-0.4 g/kg/month. Data from Germany 
show a tendency for low doses, with an average dose of 
199 mg/kg per 4 weeks for IVIG, and 343 mg/kg per 
4 weeks for SCIG [75]. Clinical immunologists were 
typically present to order higher doses (0.4-0.5 mg/kg), 
especially in patients with bronchiectasis, probably as an 
analogy of PID [1,2,45]. 
The duration of replacement treatment is often limited to 
6-12 months, but clinical practice is not universal. Agostini 
et al. recommended that treatment discontinuation may be 
considered in patients with a stable primary condition, who 
have received IgRT for more than a year and who have not 
reported infectious episodes during this period [76]. In the 
German SINGS study, 24.1% of patients had their treatment 
temporarily interrupted over a mean of 11.6 ±6.3 months 
[75]. Recent reports showed that IgRT is given regardless 
of the season, although discontinuation in the summer was 
recommended by an expert opinion [45, 75, 76]. 
The main method of assessing treatment efficacy is 
the reduction of infection rate or the decrease in infection 
severity, but the Ig trough level is also considered [2, 45]. 
To make recommendations clearer in recent years, sev-
eral countries developed their own guidelines on the proper 
use of IgRT in SIDs [77, 78]. They differ by the adopted 
eligibility criteria, including the number of infections, the 
need for course of antibiotics prophylaxis, or specific anti-
body assessment (Table 2). 
The guidelines of the European Medicines Agency 
(EMA) [80] state that patients with severe or recurrent bac-
terial infections, ineffective antibiotic treatment, and vacci-
nation failure (i.e., failure to mount at least a two-fold rise 
in an IgG antibody titre to conjugated pneumococcal poly-
saccharide vaccine) and/or hypogammaglobulinemia (de-
fined as IgG level < 4 g/l), are eligible for IVIG therapy. 
The recommended primary endpoint to assess treatment 
efficacy is the rate of serious bacterial infections (< 1.0 
infection/patient/year), which are defined as bacteremia or 
sepsis, bacterial meningitis, osteomyelitis, septic arthritis, 
bacterial pneumonia, or visceral abscess. The secondary 
endpoints are IgG through levels, all other infections, an-
tibiotic treatment, days lost from work or school, hospital-
izations, and fever episodes [79]. There are no clear criteria 
developed for Poland. 
Conclusions 
On the basis of the available study results and pub-
lished meta-analyses, we do not recommend routine re-
placement treatment with immunoglobulin products in 
patients with SID. 
The decision to initiate replacement therapy should 
be individualized and based on a combination of clinical 
history, evidence of infections, and vaccination testing for 
diagnosis. In Poland, we advocate for reimbursement for 
vaccines and diagnostic vaccination response in SID be-
fore IgRT. 
We suggest that management teams should include 
a clinical immunologist experienced in the treatment of 
humoral immunodeficiencies. 
The use of SC immunoglobulin in patients with SID 
should be available; however, it is mainly based on limited 
open trials or cohorts and PID’s experience. Formal trials 
are needed for the use of SCIG and fSCIG in SID. 
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